Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib

Author： White W.B.   Faich G.   Borer J.S.   Makuch R.W.  

Publisher： Elsevier

ISSN： 1062-1458

Source： ACC Current Journal Review, Vol.12, Iss.6, 2003-11, pp. : 14-15

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Efficacy and Safety of the Selective Cyclooxygenase-2 Inhibitor Celecoxib in the Treatment of Rheumatoid Arthritis and Osteoarthritis in Japan

By  

Digestion, Vol. 83, Iss. 1-2, 2010-11 ,pp. : 108-123

Karger

Access to resources Recommend Favorite

Tolerability of Selective Cyclooxygenase Inhibitor, Celecoxib, in Patients with Analgesic Intolerance

By Çelik Gülfem   Paşaoğlu Gülden   Bavbek Sevim   Abadoğlu Öznur   Dursun Berna   Mungan Dilşad   Mısırlıgil Zeynep  

Journal of Asthma, Vol. 42, Iss. 2, 2004-03 ,pp. : 127-131

Informa Healthcare

Access to resources Recommend Favorite

The cytotoxicity of celecoxib towards cardiac myocytes is cyclooxygenase-2 independent

By Hasinoff Brian   Patel Daywin   Wu Xing  

Cardiovascular Toxicology, Vol. 7, Iss. 1, 2007-03 ,pp. : 19-27

Humana Press, Inc

Access to resources Recommend Favorite

The cardiovascular safety of celecoxib

By Liew Danny   Krum Henry  

Future Cardiology, Vol. 1, Iss. 6, 2005-11 ,pp. : 709-722

Future Medicine

Access to resources Recommend Favorite

Hydroxychloroquine Use Is Associated With Decreased Incident Cardiovascular Events in Rheumatoid Arthritis Patients

By  

JOURNAL OF THE AMERICAN HEART ASSOCIATION, Vol. 5, Iss. 1, 2016-01 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite